SCHEMBL26373752

SCHEMBL26373752

Cc1ccc2c(CO)nccc2c1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ NOS2 P35228 4/20 0.41
▸ NOS3 P29474 3/20 0.41
▸ DYRK1A Q13627 2/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CCR1 P32246 1/20 0.34
▸ CCR5 P51681 1/20 0.34
▸ CCR8 P51685 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ MAOA P21397 1/20 0.34
▸ POLB P06746 1/20 0.31
▸ MAPT P10636 2/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26373119 0.84 PDE3B (0.42) PDE3BPDE3ANOS2NOS3ALDH1A1
SCHEMBL25371939 0.77 NOS3 (0.34) NOS2NOS3ALDH1A1LMNAKDM4E
SCHEMBL25379029 0.76 PDE10A (0.53) PDE3BPDE3AALDH1A1LMNAKDM4E
SCHEMBL3344492 0.76 NOS3 (0.48) PDE3BPDE3ANOS2NOS3DYRK1A
SCHEMBL30401972 0.76 NOS2 (0.59) NOS2NOS3ALDH1A1LMNAKDM4E
SCHEMBL24399752 0.75 PARP1 (0.36) PDE3BPDE3ANOS2NOS3ALDH1A1
SCHEMBL30402388 0.75 PARP1 (0.36) PDE3BPDE3ANOS2NOS3ALDH1A1
SCHEMBL24399590 0.75 FLT1 (0.38) PDE3BPDE3ANOS2NOS3ALDH1A1
SCHEMBL30402640 0.75 FLT1 (0.38) PDE3BPDE3ANOS2NOS3ALDH1A1
SCHEMBL29015210 0.73 LNPEP (0.33) NOS2NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM PDE3B 1633/4885PDE3A 1344/4885NOS2 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback